Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 1.00 |
| ▸ | FADS1 | O60427 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 0.97 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.72 |
| ▸ | HTT | P42858 | 3/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.72 |
| ▸ | PRNP | P04156 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.69 |
| ▸ | AHR | P35869 | 1/20 | 0.69 |
| ▸ | GLA | P06280 | 1/20 | 0.69 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29352479 | 1.00 | EGFR (1.00) | EGFRFADS1LCKERBB2HTT | |
| Hydrochloric Acid SCHEMBL9017042 | 0.98 | EGFR (1.00) | EGFRFADS1LCKERBB2HTT | |
| SCHEMBL4740533 | 0.88 | EGFR (0.82) | EGFRFADS1LCKERBB2HTT | |
| SCHEMBL4355658 | 0.88 | EGFR (1.00) | EGFRFADS1LCKERBB2HTT | |
| Hydrochloric Acid SCHEMBL11089290 | 0.87 | EGFR (0.80) | EGFRFADS1LCKERBB2HTT | |
| Hydrochloric Acid SCHEMBL9017032 | 0.86 | EGFR (0.78) | EGFRFADS1LCKERBB2HTT | |
| SCHEMBL31060510 | 0.84 | EGFR (1.00) | EGFRFADS1LCKERBB2HTT | |
| SCHEMBL4783154 | 0.84 | KDM4E (1.00) | EGFRFADS1LCKERBB2HTT | |
| SCHEMBL1262804 | 0.84 | EGFR (1.00) | EGFRFADS1LCKERBB2HTT | |
| SCHEMBL4738594 | 0.84 | EGFR (0.76) | EGFRFADS1LCKERBB2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1734 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008089307-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| WO-2008089310-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| US-20070184055-A1 | TREATMENT WITH ANTI-ERBB2 ANTIBODIES | GENENTECH, INC. | 2007-08-09 | — | — | US | claimed |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | claimed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | claimed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | claimed |
| US-20030086924-A1 | Treatment with anti-ErbB2 antibodies | GENENTECH, INC. | 2003-05-08 | — | — | US | claimed |
| EP-4748453-A2 | METHODS OF TREATING LOCALLY ADVANCED OR METASTATIC BREAST CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747282-A1 | ACTIVATABLE TYROSINE-PROTEIN KINASE MEMBRANE RECEPTOR (ROR) ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Exelixis, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747284-A1 | ACTIVATABLE ROR BINDING AGENTS AND USES THEREOF | Exelixis, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747283-A1 | TYROSINE-PROTEIN KINASE MEMBRANE RECEPTOR 1 (ROR1) ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Exelixis, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747408-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | GENENTECH, INC. (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260139315-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | GENENTECH, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| EP-1119349-A2 | EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS FOR TREATING HYPERSECRETION OF MUCUS IN THE LUNGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000010588-A9 | EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS FOR TREATING HYPERSECRETION OF MUCUS IN THE LUNGS | UNIV CALIFORNIA (US) | 2000-08-10 | — | — | WO | disclosed |
| US-6100254-A | Inhibitors of protein tyrosine kinases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2000-08-08 | — | — | US | disclosed |
| WO-2000010588-A2 | EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS FOR TREATING HYPERSECRETION OF MUCUS IN THE LUNGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-03-02 | — | — | WO | disclosed |
| WO-1999019306-A2 | 2,3-BENZODIAZEPIN-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF PROTEIN TYROSINE KINASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1999-04-22 | — | — | WO | disclosed |
| EP-0520722-B1 | Therapeutic preparations containing quinazoline derivatives | ZENECA LTD (GB) | 1996-12-27 | — | — | EP | disclosed |
| EP-0520722-A1 | Therapeutic preparations containing quinazoline derivatives | ZENECA LIMITED (GB) | 1992-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260139315-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | APOL1, PDCD1LG2, PRSS1 | EGFR 264/4885FADS1 1832/4885LCK 2338/4885 |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | IRF3, PML, TPMT | EGFR 1445/4885FADS1 4484/4885LCK 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.